Literature DB >> 27085966

Reports of 17 Chinese patients with tumor-induced osteomalacia.

Wei-Jia Yu1, Jin-Wei He1, Wen-Zhen Fu1, Chun Wang2, Zhen-Lin Zhang3.   

Abstract

Tumor-induced osteomalacia (TIO) is a rare acquired form of hypophosphatemic osteomalacia, which is usually attributed to the overproduction of fibroblast growth factor 23 (FGF-23) by benign mesenchymal neoplasms. Localization and thereafter surgical resection of tumors lead to a cure. The present study aimed to investigate the clinical data, diagnostic methods, and follow-up after tumor resection at one medical center in Shanghai to characterize the profile of this rare disorder and to share our successful experience in diagnosis and treatment. Twenty-three patients with adult-onset hypophosphatemia osteomalacia seen in Shanghai Sixth People's Hospital from 2009 to 2014 and 95 normal individuals were enrolled. After taking a medical history and performing a physical examination, we analyzed the laboratory results (including the serum FGF-23 levels) and localized the tumors by 18F-fluorodeoxyglucose positron emission tomography and computed tomography (18F-FDG PET/CT), 99mTc-octreotide (99mTc-OCT) scintigraphy, and magnetic resonance imaging (MRI). On the basis of the results of laboratory tests and imaging findings, tumor resection was conducted in 17 patients with a certain diagnosis of TIO. The results demonstrated that the 17 patients (nine men and eight women, average age 46.6 ± 12.9 years) had TIO. FGF-23 level was elevated in 94.1 % of patients (16 of 17 patients) . Serum phosphorus level decreased in 100 % of patients. 18F-FDG PET/CT revealed five tumors, 99mTc-OCT scintigraphy revealed two tumors, physical examination revealed nine tumors, and MRI revealed one tumor, among which 58.8 % of the causative tumors (10 of 17 tumors) were located in the lower extremities. After tumor resection, serum phosphorus levels normalized in 100 % of patients (all 17 patients) in 4-21 days and FGF-23 levels decreased in 90 % of patients (nine of ten patients). We found 64.7 % of the tumors (11 of 17 tumors) were phosphaturic mesenchymal tumors or a phosphaturic mesenchymal tumor mixed connective tissue variant. Measurement of serum phosphorus and FGF-23 levels in patients with suspected TIO is of paramount importance for diagnosing of TIO. 18F-FDG PET/CT, 99mTc-OCT scintigraphy, and physical examination play a considerable role in revealing TIO-associated tumors. TIO-associated tumors were more frequently located in the lower extremities than in other places; thus, the lower extremities need to be carefully checked. Complete surgical resection results in normalization of parameters in laboratory tests and relief of symptoms of TIO patients.

Entities:  

Keywords:  18F-Fluorodeoxyglucose positron emission tomography and computed tomography; Fibroblast growth factor 23; Tumor-induced osteomalacia

Mesh:

Substances:

Year:  2016        PMID: 27085966     DOI: 10.1007/s00774-016-0756-9

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  38 in total

1.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

Review 2.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

3.  Localisation of mesenchymal tumours by somatostatin receptor imaging.

Authors:  Suzanne M Jan de Beur; Elizabeth A Streeten; A Cahid Civelek; Edward F McCarthy; Liliana Uribe; Stephen J Marx; Olufunmilayo Onobrakpeya; Lawrence G Raisz; Nelson B Watts; Michael Sharon; Michael A Levine
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

4.  Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors.

Authors:  Thomas O Carpenter; Bruce K Ellis; Karl L Insogna; William M Philbrick; John Sterpka; Richard Shimkets
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

5.  Tumor-induced osteomalacia: a single center experience.

Authors:  Varsha S Jagtap; Vijaya Sarathi; Anurag R Lila; Gaurav Malhotra; Shilpa S Sankhe; Tushar Bandgar; Padmavathy Menon; Nalini S Shah
Journal:  Endocr Pract       Date:  2011 Mar-Apr       Impact factor: 3.443

6.  Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients.

Authors:  Swati Jadhav; Rajeev Kasaliwal; Vikram Lele; Venkatesh Rangarajan; Piyush Chandra; Hina Shah; Gaurav Malhotra; Varsha S Jagtap; Sweta Budyal; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-12       Impact factor: 3.478

7.  Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using 68Ga-DOTANOC PET/CT.

Authors:  Niraj Naswa; Punit Sharma; Rakesh Kumar; Arun Malhotra; Chandrasekhar Bal
Journal:  Clin Nucl Med       Date:  2013-08       Impact factor: 7.794

Review 8.  Case report: Solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature.

Authors:  S C Chua; S R O'Connor; W L Wong; R H Ganatra
Journal:  Br J Radiol       Date:  2008-04       Impact factor: 3.039

9.  Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy.

Authors:  Stephen F Hodgson; Bart L Clarke; Peter J Tebben; Brian P Mullan; William P Cooney; Thomas C Shives
Journal:  Endocr Pract       Date:  2006 Jan-Feb       Impact factor: 3.443

10.  Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.

Authors:  Mouhammed Amir Habra; Camilo Jimenez; Su-Chen Eileen Huang; Gilbert J Cote; William A Murphy; Robert F Gagel; Ana O Hoff
Journal:  Endocr Pract       Date:  2008-12       Impact factor: 3.443

View more
  17 in total

1.  Successful Localization Using 68Ga-DOTATOC PET/CT of a Phosphaturic Mesenchymal Tumor Causing Osteomalacia in a Patient with Concurrent Follicular Lymphoma.

Authors:  Sejin Ha; Sujin Park; Hyunji Kim; Heounjeong Go; Seung Hun Lee; Ji Yoon Choi; Jung Yong Hong; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2018-09-12

Review 2.  Paraneoplastic musculoskeletal disorders: review and update for radiologists.

Authors:  Kimia Khalatbari Kani; Jack A Porrino; Michael E Mulligan; Felix S Chew
Journal:  Skeletal Radiol       Date:  2022-05-23       Impact factor: 2.199

3.  High prevalence of vertebral deformity in tumor-induced osteomalacia associated with impaired bone microstructure.

Authors:  X Ni; W Guan; Y Jiang; X Li; Y Chi; Q Pang; W Liu; R Jiajue; O Wang; M Li; X Xing; H Wu; L Huo; Y Liu; J Jin; X Zhou; W Lv; L Zhou; Y Xia; Y Gong; W Yu; W Xia
Journal:  J Endocrinol Invest       Date:  2022-09-13       Impact factor: 5.467

4.  Acquired hypophosphatemic osteomalacia is easily misdiagnosed or neglected by rheumatologists: A report of 9 cases.

Authors:  Ling Li; Shu-Xia Wang; Hong-Mei Wu; Dong-Lan Luo; Guang-Fu Dong; Yuan Feng; Xiao Zhang
Journal:  Exp Ther Med       Date:  2018-04-27       Impact factor: 2.447

5.  Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.

Authors:  Qing-Yao Zuo; Hong Wang; Wei Li; Xiao-Hui Niu; Yan-Hong Huang; Jia Chen; Yu-Hua You; Bao-Yue Liu; Ai-Min Cui; Wei Deng
Journal:  BMC Musculoskelet Disord       Date:  2017-09-21       Impact factor: 2.362

Review 6.  Ameloblastic Fibroodontoma of Mandible Causing Tumor Induced Osteomalacia: A Case Report with Review of 88 Phosphaturic Oral Neoplasms.

Authors:  Deepika Mishra; Harpreet Kaur; Ashu Seith Bhalla; Smita Manchanda; Jithin Sasikumar; Bhaskar Agarwal; Ajoy Roychoudhury
Journal:  Head Neck Pathol       Date:  2021-01-04

7.  Prolonged Hypophosphatemia and Intensive Care After Curative Surgery of Tumor Induced Osteomalacia: A Case Report.

Authors:  Eeva M Ryhänen; Camilla Schalin-Jäntti; Niina Matikainen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-03       Impact factor: 5.555

8.  A case report of phosphaturic mesenchymal tumor-induced osteomalacia.

Authors:  Weiqian Wu; Chongyang Wang; Jianwei Ruan; Feng Chen; Ningjun Li; Fanghu Chen
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 9.  Phosphaturic mesenchymal tumor and related wound problem.

Authors:  Xian Xiao; Xiaofang Sun; Pengwen Ni; Yao Huang; Ting Xie
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

10.  Osteomalacia, renal Fanconi syndrome, and bone tumor.

Authors:  Manting Gou; Zhongshu Ma
Journal:  J Int Med Res       Date:  2018-04-03       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.